echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The legal representative of a pharmaceutical company was investigated on suspicion of bribery

    The legal representative of a pharmaceutical company was investigated on suspicion of bribery

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 10, the website of the State Supervision Commission of the Central Commission for Discipline Inspection found that Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.


    Aiqicha shows that Dai Longyong, a shareholder of Jiangxi Yongchang Pharmaceutical Co.


    According to public information, Jiangxi Yongchang Pharmaceutical Co.


    In 2021, medical anti-corruption in various places is in full swing

    In 2021, medical anti-corruption in various places is in full swing

    Yunnan: 12 bribery officers detained

    Yunnan: 12 bribery officers detained

    On April 4, the website of the State Supervision Commission of the Central Commission for Discipline Inspection released a piece of information: "Yunnan severely investigated and dealt with corruption in the medical field 12 bribery personnel were detained in accordance with the law"!

    It is reported that the Yunnan Provincial Commission for Discipline Inspection announced publicly on April 1 that four corporate executives were suspected of bribing Yuan Bin, the former party secretary of Kunming Medical University.


    The Discipline Inspection Commission of Yunnan Province also released information in January and March this year.


    Anhui: Director of Pharmacy Department was arrested for taking bribes, leading 22 pharmaceutical companies

    Anhui: Director of Pharmacy Department was arrested for taking bribes, leading 22 pharmaceutical companies

    On April 1, the People’s Procuratorate of Wuhe County, Anhui Province announced an indictment: Shi Moumou, the former director of the ** Department of the First Affiliated Hospital of Bengbu Medical College, was arrested by the Wuhe County Public Security Bureau on September 30, 2020 on suspicion of accepting bribes.


    During his work in the First Affiliated Hospital of Beng Medical, Shi took advantage of his position as the purchaser, deputy director, and director of the Department of Medicine, and accepted personnel from multiple pharmaceutical companies in order to coordinate relations, maintain or expand the medical company’s work in the First Affiliated Hospital of Beng Medical.


    Procurement of medical equipment and drugs named by the Central Commission for Discipline Inspection

    Procurement of medical equipment and drugs named by the Central Commission for Discipline Inspection

    On January 19 this year, the website of the Central Commission for Discipline Inspection and the State Supervision Commission issued a document directly naming the issue of medical corruption, focusing on cracking down on the issue of medicine and equipment purchase rebates.


    Medical staff use the right of prescriptions in their hands to "issue a commission", use medical equipment, drug consumables and other medical and health resources to seek benefits and even commit crimes on duty.


    In response to these corruption issues, the state has also issued many policies to control the "marginal behaviors of these laws.


    And the "Memorandum of Cooperation on Carrying out the Information Exchange and Sharing of Commercial Bribery Cases in the Pharmaceutical Field" signed by the Supreme People's Court and the National Medical Insurance Bureau, establish a regular notification system, and continue to deepen the collaborative cooperation in the management of commercial bribery in the pharmaceutical field.


    Multi-departmental linkage and a series of combined punches are aimed at eradicating outstanding problems such as benefit transmission, black-box operation, and false price increase in the process of pharmaceutical bidding or procurement.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.